查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1494683

基因生物標記市場：按產品類型、適應症和最終用戶分類 - 全球預測 2024-2030

Genomic Biomarker Market by Product (Consumables, Services, Software), Type (Predictive Biomarkers, Prognostic Biomarkers), Disease Indication, End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年基因生物標記市場規模為44億美元，預計2024年將達46.7億美元，2030年將達到69.2億美元，複合年成長率為6.67%。

基因生物標記是DNA或RNA分子，用於檢查基因與環境之間的複雜關係，大大增強了對健康、疾病和農產品的理解和管理。這些生物標記在早期疾病診斷和風險評估中發揮著至關重要的作用，使得在症狀出現之前更容易識別潛在的健康問題，例如癌症和心血管疾病。基因生物標記提供個人化醫療，允許根據每個人的基因圖譜客製化治療，最佳化治療效果並最大限度地減少副作用。製藥領域在開發特異性針對疾病分子基礎的標靶藥物中從基因生物標記中受益匪淺。在農業中，基因生物標記能夠培育出提高產量並抵抗環境壓力的作物品種。基因生物標記廣泛應用於農業研究、醫療保健和農業。隨著基因組標記在個人化醫療中的應用不斷擴大，醫療保健和製藥領域對基因生物標記的需求正在迅速增加。此外，政府對基因生物標記研究和開發的監管支持不斷增加，正在推動對先進、更有效的基因生物標記的需求。然而，與這些生物標記開發相關的技術限制阻礙了需求。此外，將機器學習和人工智慧整合到基因組研究中將增強基因生物標記的預測能力。

主要市場統計
基準年[2023] 44億美元
預測年份 [2024] 46.7億美元
預測年份 [2030] 69.2億美元
複合年成長率（%） 6.67%

區域洞察

由於醫療基礎設施的改善和生物醫學研究投資的大幅增加，美洲，尤其是北美，對基因生物標記的需求強勁。由於該地區癌症和心血管疾病等慢性疾病的高盛行率，個人化醫療方法正在擴大基因生物標記的應用。此外，研究機構和生技公司之間的持續合作將加強基因生物標記的創新，支持政府的基因組研究資助政策，並規範進展以擴大馬蘇地區的需求。由於醫療保健和診斷領域的快速擴張，該地區的基因生物標記市場正在快速成長。在中國、日本、韓國等國家，生物技術領域正在快速發展，對基因生物標記有強烈需求。醫療保健支出的增加、個人化醫療意識的提高以及公共和私人對基因組研究投資的增加是關鍵促進因素。由於先進醫療保健系統和次世代定序儀技術的普及，歐洲和中東地區正在呈現快速成長。在歐盟 (EU)，由於政府對基因組研究和國家間合作研究的資助，基因生物標記的引入顯著擴大。由於更加重視改善醫療保健系統以及增加對醫療保健產業的外國投資，非洲地區具有成長潛力。

FPNV定位矩陣

FPNV 定位矩陣對於評估基因生物標記市場供應商的市場定位至關重要。此矩陣提供了對供應商的全面評估，並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可對基因生物標記市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻，您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外，該分析還提供了對該行業競爭性質的寶貴見解，包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在基因生物標記市場中的地位進行全面評估，使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 更多地使用基因生物標記來早期檢測和診斷慢性疾病
      • 政府和監管部門對基因生物標記研究的支持
      • 擴大基因生物標記在個人化醫療的應用
    • 抑制因素
      • 與開發基因生物標記相關的高成本和技術問題
    • 機會
      • 整合人工智慧、機器學習和基因組研究
      • 人們對開發先進的非侵入性基因生物標記越來越感興趣
    • 任務
      • 關於使用基因生物標記的倫理和法律問題
  • 市場區隔分析
    • 類型：擴大預後生物標記在藥物研究中的使用
    • 最終使用者：擴大基因生物標記在診斷中心的應用
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章基因生物標記市場：依產品

  • 消耗品
  • 服務
  • 軟體

第7章基因生物標記市場：依類型

  • 預測生物標記
  • 預後生物標記

第8章基因生物標記市場：依疾病指示

  • 心血管疾病
  • 神經系統疾病
  • 腫瘤學
  • 腎臟疾病

第 9 章基因生物標記市場：依最終用戶分類

  • 診斷中心
  • 醫院
  • 調查機構

第10章美洲基因生物標記市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區基因生物標記市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的基因生物標記市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • Bio-Rad 推出創新的多重數位 PCR 檢測以增強乳癌監測
    • 使用 Biofidelity 的 ASPYRE-Lung RUO 試劑增強快速基因生物標記分析簡介
    • Illumina 在腫瘤學領域取得突破 TruSight Oncology 500 ctDNA v2 為固態腫瘤基因組分析提供支持
  • 戰略分析和建議

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-CB04E0565332

[194 Pages Report] The Genomic Biomarker Market size was estimated at USD 4.40 billion in 2023 and expected to reach USD 4.67 billion in 2024, at a CAGR 6.67% to reach USD 6.92 billion by 2030.

Genomic biomarkers are DNA or RNA molecules that are used to examine the complex relationships between genetics and the environment and significantly enhance understanding and management of health, diseases, and agricultural outputs. These biomarkers play a pivotal role in early disease diagnosis and risk assessment, facilitating the identification of potential health issues such as cancer and cardiovascular diseases before they manifest symptoms. Genomic biomarkers offer personalized medicine and enable the customization of treatments to each individual's genetic profile, optimizing therapy effectiveness and minimizing adverse effects. The pharmaceutical sector benefits immensely from genomic biomarkers in the development of targeted medications that specifically address the molecular basis of diseases. In agriculture, they enable the breeding of crop varieties with enhanced yields and resistance to environmental stresses. Genomic biomarkers are widely used in agricultural research, healthcare, and farming practices. The growing applications of genomic markers for personalized medicine are surging the need for genomic biomarkers in the healthcare and pharmaceutical sectors. Additionally, the growing regulatory support by the governments for research and development of genomic biomarkers is driving the demand for advanced and more effective genomic biomarkers. However, technical limitations associated with the development of these biomarkers hinder the demand. Moreover, the integration of machine learning and AI with genomic studies enhances the predictive ability of genomic biomarkers.

KEY MARKET STATISTICS
Base Year [2023] USD 4.40 billion
Estimated Year [2024] USD 4.67 billion
Forecast Year [2030] USD 6.92 billion
CAGR (%) 6.67%

Regional Insights

In the Americas, particularly North America, is exhibiting a robust demand for genomic biomarkers with the well-established healthcare infrastructure and a significant increase in investments in biomedical research. With a high prevalence of chronic diseases such as cancer and cardiovascular diseases within the region, personalized medicine approaches are thus increasing the application of genomic biomarkers. Moreover, ongoing collaborations between research institutes and biotechnology companies enhance the innovation of genomic biomarkers, support government policies on genomics research funds, and regulate advancements to expand the demand within the region. This region is experiencing rapid growth in the genomic biomarker market with the surging expansion of the healthcare and diagnostic sectors. Countries such as China, Japan, and South Korea have robust needs for genomic biomarkers due to their fast-growing biotech sectors. Rising healthcare expenditure, rising awareness about personalized medicine, and an increase in public and private investment in genomic research are important drivers. Europe and the Middle East regions show rapid growth driven by advanced healthcare systems and widespread adoption of next-generation sequencing technologies. Government funding in genomics and collaborations across countries in the European Union are significantly growing the adoption of genomic biomarkers. There is potential growth in the African region due to an increasing focus on improving healthcare systems and rising foreign investments in the healthcare sector.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Genomic Biomarker Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing usage of genomic biomarkers in early detection and diagnosis of chronic disease
      • Governments and regulatory support for genomic biomarker research
      • Growing applications of genomic biomarkers in personalized medicine
    • Market Restraints
      • High cost and technical issues associated with developing genomic biomarkers
    • Market Opportunities
      • Integration of AI and machine learning with genomic studies
      • Growing interest in developing advanced noninvasive genomic biomarkers
    • Market Challenges
      • Ethical and legal concerns regarding the use of genomic biomarkers
  • Market Segmentation Analysis
    • Type: Proliferating use of prognostic biomarkers in pharmaceutical research
    • End-user: Expanding application of genomic biomarkers in diagnostic centers
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Genomic Biomarker Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Genomic Biomarker Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Bio-Rad Introduces Revolutionary Multiplexed Digital PCR Assay for Enhanced Breast Cancer Research

Bio-Rad Laboratories, Inc. unveiled its groundbreaking ddPLEX ESR1 Mutation Detection Kit. his kit marks a significant advance in the oncology sector by offering an ultrasensitive, multiplexed digital PCR assay designed to detect, differentiate, and quantitatively assess seven critical ESR1 mutations from a single sample. This development expands Bio-Rad's portfolio in digital PCR solutions and strengthens its commitment to supporting oncology researchers in biomarker discovery and clinical trials, thereby improving patient care continuity and treatment efficacy. [Published On: 2024-04-01]

Biofidelity's Introduction ASPYRE-Lung RUO Reagents for Enhanced and Rapid Genomic Biomarker Analysis

Biofidelity unveiled the ASPYRE-Lung RUO, a cutting-edge reagent product designed to simplify and expedite the detection of genomic biomarkers in labs globally. The ASPYRE-Lung technology uses standard PCR instruments already present in most laboratories, eliminating the need for specialized staff or complex setups. Its high sensitivity facilitates the use of tissue samples with minimal tumor content, considerably lowering the threshold compared to traditional assays. The ASPYRE-Lung RUO is poised to revolutionize diagnostic tests, ensuring high-quality results with quick turnarounds for diverse research applications. [Published On: 2023-12-06]

Illumina's Breakthrough in Oncology TruSight Oncology 500 ctDNA v2 Enhances Solid Tumor Genomic Profiling

Illumina Inc. introduced the latest version of its liquid biopsy assay, the TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2). This cutting-edge research tool offers noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA), providing critical data when traditional tissue sample testing is not feasible. As Illumina gears up to integrate automation in their assays, this innovation stands poised to redefine the landscape of tumor profiling, rendering it an increasingly indispensable tool in precision oncology. [Published On: 2023-11-01]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Genomic Biomarker Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Genomic Biomarker Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., APIS Assay Technologies Limited, Augurex Life Sciences Corp, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocrates Life Sciences AG, Biostarks Laboratories SA, Bruker Corporation, CD Genomics, Charles River Laboratories, Inc., DH Life Sciences, LLC., Elo Health, Inc., Eurofins Scientific corporation, F. Hoffmann-La Roche Ltd, Illumina Inc., Merck KGaA, Myriad Genetics, Inc, Owkin, Inc, and Thermo Fisher Scientific company.

Market Segmentation & Coverage

This research report categorizes the Genomic Biomarker Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Consumables
    • Services
    • Software
  • Type
    • Predictive Biomarkers
    • Prognostic Biomarkers
  • Disease Indication
    • Cardiovascular Diseases
    • Neurological Diseases
    • Oncology
    • Renal Disorders
  • End-User
    • Diagnostic Centers
    • Hospitals
    • Research Institutions
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing usage of genomic biomarkers in early detection and diagnosis of chronic disease
      • 5.1.1.2. Governments and regulatory support for genomic biomarker research
      • 5.1.1.3. Growing applications of genomic biomarkers in personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and technical issues associated with developing genomic biomarkers
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of AI and machine learning with genomic studies
      • 5.1.3.2. Growing interest in developing advanced noninvasive genomic biomarkers
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical and legal concerns regarding the use of genomic biomarkers
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Proliferating use of prognostic biomarkers in pharmaceutical research
    • 5.2.2. End-user: Expanding application of genomic biomarkers in diagnostic centers
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Genomic Biomarker Market, by Product

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Services
  • 6.4. Software

7. Genomic Biomarker Market, by Type

  • 7.1. Introduction
  • 7.2. Predictive Biomarkers
  • 7.3. Prognostic Biomarkers

8. Genomic Biomarker Market, by Disease Indication

  • 8.1. Introduction
  • 8.2. Cardiovascular Diseases
  • 8.3. Neurological Diseases
  • 8.4. Oncology
  • 8.5. Renal Disorders

9. Genomic Biomarker Market, by End-User

  • 9.1. Introduction
  • 9.2. Diagnostic Centers
  • 9.3. Hospitals
  • 9.4. Research Institutions

10. Americas Genomic Biomarker Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Genomic Biomarker Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Genomic Biomarker Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Bio-Rad Introduces Revolutionary Multiplexed Digital PCR Assay for Enhanced Breast Cancer Research
    • 13.3.2. Biofidelity's Introduction ASPYRE-Lung RUO Reagents for Enhanced and Rapid Genomic Biomarker Analysis
    • 13.3.3. Illumina's Breakthrough in Oncology TruSight Oncology 500 ctDNA v2 Enhances Solid Tumor Genomic Profiling
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. GENOMIC BIOMARKER MARKET RESEARCH PROCESS
  • FIGURE 2. GENOMIC BIOMARKER MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENOMIC BIOMARKER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GENOMIC BIOMARKER MARKET DYNAMICS
  • FIGURE 7. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. GENOMIC BIOMARKER MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. GENOMIC BIOMARKER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENOMIC BIOMARKER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENOMIC BIOMARKER MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL GENOMIC BIOMARKER MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY CONSUMABLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY RENAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY RENAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 49. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 50. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 57. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 58. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 65. CANADA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 66. CANADA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 73. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 74. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 81. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 82. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 102. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 109. CHINA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 110. CHINA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 117. INDIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 118. INDIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 125. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 126. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 133. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 134. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 141. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 142. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 150. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 157. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 158. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 173. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 174. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 181. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 182. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 189. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 190. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 207. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 208. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 215. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 216. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 223. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 224. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 231. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 232. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 239. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 240. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 247. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 248. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 255. ITALY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 256. ITALY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 264. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 271. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 272. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 279. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 280. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 287. POLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 288. POLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 295. QATAR GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 296. QATAR GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 303. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 304. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 305. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 306. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 312. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 314. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 320. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 322. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 327. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 328. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 329. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 330. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 331. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 332. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 333. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 334. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 335. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 336. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 337. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 338. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 339. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 340. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 341. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 342. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 344. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 346. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 348. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 350. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 351. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 352. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 353. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 354. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 355. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 356. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 357. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 358. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 359. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 360. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 361. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 362. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 364. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MIL